Clinigen, the global specialist pharmaceutical services group, has appointed Nihad Hasagic as Senior Vice President for Clinigen Lifecycle Services (SVP CLS). Reporting to the Chief Executive Officer, this appointment emphasizes Clinigen’s commitment to accelerating growth, enhancing its market position, and driving long-term value for clients and investors, ultimately contributing to improved patient outcomes.

CLS plays a key role in Clinigen’s growing service portfolio, helping to facilitate accelerated pathways to patients for critical medicines at every stage of their lifecycle, even in complex markets.

This important appointment is part of a larger leadership restructuring aimed at enhancing the company’s focus on reaching its growth goals and seizing critical market opportunities.

About Nihad Hasagic

Previously, as SVP of Strategic Initiatives, Hasagic was pivotal in successful acquisitions and the development of the company’s core growth strategy, including his foundational work in launching CLS and shaping its commercial strategy. This track record, combined with over 20 years of experience in the healthcare, life science, and specialty chemicals industries, leading multiple acquisitions and corporate initiatives, makes him exceptionally well-suited to lead the new division and capture the opportunities in the rapidly expanding specialist pharma services market. His deep market understanding and proven ability to drive important growth will be critical to establishing CLS as a significant value driver and market differentiator.

Jerome Charton, CEO of Clinigen, said, “There is no one better placed than Nihad to lead Clinigen Lifecycle Services as we continue to strengthen our market presence, capture high-growth specialist pharma services opportunities, and drive enhanced returns for our investors. The direct reporting line for Keith in Corporate Development will also be instrumental in accelerating our expansion. CLS plays a vital role in strengthening the safety and accessibility of new medicines for patients, and under Nihad’s leadership, we are confident in its ability to deliver significant value to our clients and, most importantly, contribute to positive outcomes for the patients they serve.”